Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).

Thyrotoxicosis is an adverse event associated with immune checkpoint inhibitors (ICPis) that occurs in 0.6 to 3.2% of treated patients, depending on ICPi class.